KRAS and neoplasm: Nevertheless, a proof-of-concept study in mice harboring various KRAS-mutant tumor xenografts showed that an anti-mutant KRAS antibody (RT11) in able to penetrate tumor cells and inhibit KRAS-mutated tumor-cell proliferation and disease progression (26).